BioWorld-International-2010-03-17
Ablynx Growing Post-IPO, Adds $68M to Advance Nanobodies
Sans Partner, Oxford BioMedica Restarting TroVax Development
LONDON - Oxford BioMedica plc is restarting clinical development of its TroVax cancer immunotherapy 12 months after the failure of a Phase III trial in renal cancer led partner Sanofi-Aventis SA to drop the product. (BioWorld International)

